Trump Stock Purchase in Eli Lilly Raises Conflict Questions

Former President Trump purchased stock in Eli Lilly while his administration implemented policies that benefited the pharmaceutical company. The investment timing coincided with regulatory decisions favorable to drugmakers. This highlights ongoing concerns about potential conflicts of interest between policymakers and pharmaceutical companies. Medicaid managed care organizations should monitor how political relationships may influence drug pricing and coverage policies.

Pharmacy · Managed Care